Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anil Kukreja"'
Autor:
Kumar Prabhash, Amit Rauthan, Senthil Rajappa, Chirag Desai, Rajesh Mistry, Amit Dutt, Anuradha Chougule, Ravi Mohan, Pratap K Das, Rajiv Kumar, Vanita Noronha, Amit Joshi, Vijay M Patil, Binay Swarup, Anil Kukreja
Publikováno v:
Asian Journal of Oncology, Vol 03, Iss 01, Pp 039-044 (2017)
Context: Trends in epidermal growth factor receptor (EGFR) mutation based on ethnicity assist the initial selection of targeted therapy regimen. Reported incidence of EGFR mutation in Indian NSCLC patients is variable, ranging from 22% to 51.8%. Aim
Externí odkaz:
https://doaj.org/article/f5135b574d6941d59c58056871d0a86e
Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
Autor:
Amit Rauthan, Palanki Satya Dattatreya, Manish Singhal, Ram Prabu, Siddharth Naik, Anil Kukreja
Publikováno v:
Asian Journal of Oncology, Vol 01, Iss 02, Pp 084-091 (2015)
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanize
Externí odkaz:
https://doaj.org/article/c127dfe7c98d4ecbbcd122a4252693d7
Publikováno v:
EDULEARN Proceedings.
Autor:
Anil Kukreja
Publikováno v:
INTED2019 Proceedings.
Autor:
P. V. Sushma, B. Parikh, N. Huilgol, G. Saini, Anil Kukreja, S. Gupta, Binay Swarup, S. Gundeti, Amitesh Agarwal, S. Alurkar, S. Jain, K. S. Tewari, Manish Singhal, S. Nangia, A. Ramesh, A. Pathak, B. Ugile, V. Goswami, S. Rawat
Publikováno v:
Gynecologic Oncology Research and Practice
Gynecologic Oncology Research and Practice, Vol 5, Iss 1, Pp 1-12 (2018)
Gynecologic Oncology Research and Practice, Vol 5, Iss 1, Pp 1-12 (2018)
Objective In India, cervical cancer accounts for almost 14% of all female cancer cases. Although poverty continues to cast a wide net over the Indian subcontinent, the preceding three decades have borne witness to improvements in nutrition and sanita
Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
Autor:
Siddharth Naik, Manish Singhal, Anil Kukreja, Ram Prabu, Amit Rauthan, Palanki Satya Dattatreya
Publikováno v:
Asian Journal of Oncology, Vol 01, Iss 02, Pp 084-091 (2015)
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a more aggressive subtype of breast cancer and targeting the HER2 receptor has proven effective in improving the prognosis of these patients. Pertuzumab, a recombinant humanize
Autor:
Svs Deo, Raju Titus Chacko, Vinod Raina, Anil Kukreja, Shona Nag, Nalini Kilara, Binay Swarup, Sudeep Gupta, Govind Babu, Dinesh Chandra Doval, Chirag Shah, Chirag Desai, Smruti B. Koppikar
Publikováno v:
Journal of Clinical Oncology. 36:1098-1098
1098Background: There is a higher burden (29.2%-46%) of TNBC patients in India. This single arm, phase II trial evaluated the efficacy and safety of bevacizumab in combination with gemcitabine and ...
Publikováno v:
Performance Improvement. 48:9-25
During the last few decades, a number of quality improvement methodologies have been used by organizations. This article provides a brief review of the quality improvement literature related to academia and a case study using Six Sigma methodology to
Autor:
Charles P. Schmidt, Anil Kukreja
Publikováno v:
Computers & Operations Research. 32:2059-2075
The inventory system considered in this work is single echelon, N-location and continuous review in which complete pooling of stock is permitted among the locations. A model is developed for slow moving, expensive items that are common to two or more
Publikováno v:
Management Science. 47:1371-1383
This research shows that organizations with a number of “sister” plants, warehouses, or other stocking points can profit from the concept of proactive use of transshipments as an element of their inventory control policy. For certain types of par